BofA initiates Iambic Therapeutics stock with buy rating on AI drug design

🌐 Investing.com (Cyprus) —
BofA initiates Iambic Therapeutics stock with buy rating on AI drug design

AI Summary

BofA initiated coverage of Iambic Therapeutics with a Buy rating, citing the company's use of AI in drug design. The article contains no further details about its technology or valuation.

Markets Health AI & Tech Iambic Therapeutics BofA AI drug design stock coverage Buy rating

Read original source →